At AUA 2015 in New Orleans, Dr Celestia Higano (Seattle) presented the results of the STRIVE clinical trial.
The results of the TERRAIN prostate cancer clinical trial data were presented at the 2015 European Association of Urology (EAU) Congress in Madrid today.
Update on checkpoint inhibitors in urothelial bladder cancer from AUA 2015 and what's in store for new developments with this disease.
The Phase 2 TERRAIN trial met its primary endpoint (PFS) with enzalutamide beating out bicalutamide in castrate resistant prostate cancer. What next?
Medivation and Astellas provided an update at AUA 2014 on the Xtandi PREVAIL data with a breakdown for visceral and non-visceral disease.
New targets are emerging in advanced prostate cancer that may help improve outcomes and overcome adaptive resistance
